Long-Term Immunogenicity and Safety of a Conventional Influenza Vaccine in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
No previous studies have assessed the persistence of immune responses in individuals with diabetes. We conducted this study to evaluate the long-term immunogenicity and safety of an influenza vaccine in type 2 diabetic subjects compared with nondiabetic controls. A randomized and controlled study was conducted at two university hospitals during the 2012-2013 influenza season. The study vaccine was a standard-dose trivalent subunit inactivated intramuscular vaccine. Serum hemagglutination-inhibiting (HI) antibodies were measured at the time of vaccination and 1 month and 6 months after vaccination. Local and systemic reactions were recorded for 7 days. A total of 105 diabetic patients and 108 controls were included in the analysis. One month after vaccination, both the diabetic and nondiabetic groups satisfied all of the criteria of the Committee for Medical Products for Human Use (CHMP), and the immunogenicity profiles were statistically similar between the two groups. Although the vaccine was well tolerated, and all adverse reactions were mild to moderate, there was a tendency toward a reduced incidence of local reactions in the diabetic group. All values in the long-term immunogenicity profiles were statistically similar between the two groups, except for the seroprotection rate for the A/H1N1 influenza virus strain, which was significantly lower in the elderly diabetic group than that in the elderly nondiabetic group. However, in multivariate analysis, long-term immunogenicity was associated with age and prevaccination titer, regardless of diabetes status. (This study has been registered at CRIS [ https://cris.nih.go.kr/cris/en/ ] under registration no. KCT0001423.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while exenatide has been shown to cause nodular C-cell lesions without medullary thyroid carcinoma”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1810]
In the citing paper
“An increase in thyroid C-cell hyperplasia, adenomas, and medullary thyroid carcinomas was observed in preclinical rodent studies of liraglutide”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1810]
Citations
Cites
Infections in patients with diabetes mellitus: A review of pathogenesis
Alves, C., Casqueiro, J., & Casqueiro, J. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94253 · Cited by 1,147
Antibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064 · cited 1×
“A quantitative review study reported that the antibody response to the influenza vaccine is lower in elderly individuals (17).”
BackgroundDiabetes and the Severity of Pandemic Influenza A (H1N1) Infection
Allard, R., Leclerc, P., Tremblay, C., & Tannenbaum, T.-N. (2010) · Diabetes Care · doi:10.2337/dc09-2215 · Cited by 297
Song, J. Y., Cheong, H. J., Hwang, I. S., Choi, W. S., Jo, Y. M., Park, D. W., Cho, G. J., Hwang, T. G., & Kim, W. J. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.067 · Cited by 147
Self-citationValdez, R., Narayan, K. M., Geiss, L. S., & Engelgau, M. M. (1999) · American Journal of Public Health · doi:10.2105/ajph.89.11.1715 · Cited by 141
Reading, P. C., Allison, J., Crouch, E. C., & Anders, E. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6884-6887.1998 · Cited by 113
Diepersloot, R. J. A., Bouter, K. P., BEYER, W. E. P., Hoekstra, J. B. L., & Masurel, N. (1987) · Diabetologia · doi:10.1007/bf00292541 · Cited by 91
The immune response to influenza vaccination in diabetic patients
Pozzilli, P., Gale, E., Visallil, N., Baroni, M. G., Crovari, P., Frighi, V., Cavallo, M. G., & Andreani, D. (1986) · Diabetologia · doi:10.1007/bf00870139 · Cited by 90
Frasca, D., Diaz, A., Romero, M., Mendez, N. V., Landin, A. M., Ryan, J. G., & Blomberg, B. B. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.003 · Cited by 79
Quantitative review of antibody response to inactivated seasonal influenza vaccines
Seidman, J. C., Richard, S. A., Viboud, C., & Miller, M. A. (2012) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2011.00268.x · Cited by 68
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Benefits of flu vaccination for persons with diabetes mellitus: A review
Goeijenbier, M., van Sloten, T. T., Slobbe, L., Mathieu, C., van Genderen, P. J. J., BEYER, W. E. P., & Osterhaus, A. D. M. E. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.095 · Cited by 160
Who and when to vaccinate against influenza
Buchy, P., & Badur, S. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.02.040 · Cited by 123
Dissecting the interaction between COVID‐19 and diabetes mellitus
Chee, Y. J., Tan, S. K., & Yeoh, E. C. K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13326 · Cited by 96
Influenza vaccines: Evaluation of the safety profile
Trombetta, C. M., Gianchecchi, E., & Montomoli, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1423153 · Cited by 96
Dos Santos, G., Tahrat, H., & Bekkat-Berkani, R. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1446719 · Cited by 83
Saenwongsa, W., Nithichanon, A., Chittaganpitch, M., Buayai, K., Kewcharoenwong, C., Thumrongwilainet, B., Butta, P., Palaga, T., Takahashi, Y., Ato, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60213-0 · Cited by 46
Diabetes mellitus as a vaccine-effect modifier: a review
Verstraeten, T., Fletcher, M. A., Suaya, J. A., Jackson, S., Hall-Murray, C. K., Scott, D. A., Schmöele-Thoma, B., Istúriz, R., & Gessner, B. D. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1760098 · Cited by 40
Dhar, R., Ghoshal, A. G., Guleria, R., Sharma, S., Kulkarni, T., Swarnakar, R., Samaria, J., Chaudhary, S., Gaur, S., Christopher, D., et al. (2020) · Lung India · doi:10.4103/lungindia.lungindia_270_20 · Cited by 32
Vasilev, G., Kabakchieva, P., Miteva, D., Batselova, H., & Velikova, T. V. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i9.738 · Cited by 27
Bollaerts, K., Αλεξανδρίδου, Μ., & Verstraeten, T. (2019) · Vaccine X · doi:10.1016/j.jvacx.2019.100007 · Cited by 22
Fragkou, P. C., Moschopoulos, C. D., Reiter, R., Berger, T., & Skevaki, C. L. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.010 · Cited by 21
Impact of Obesity and Diabetes in Pregnant Women on Their Immunity and Vaccination
Wierzchowska-Opoka, M., Grunwald, A., Rekowska, A. K., Łomża-Łaba, A., Mekler, J., Santiago, M., Kabała, Z., Kimber-Trojnar, Ż., & Leszczyńska‐Gorzelak, B. (2023) · Vaccines · doi:10.3390/vaccines11071247 · Cited by 20
Influenza vaccination in patients affected by diabetes
Verket, M., Jacobsen, M., Schütt, K. S., Marx, N., & Müller‐Wieland, D. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac119 · Cited by 18
Assessing Vaccine Protection for Older Adults with Diabetes: A Systematic Review
Almasri, L., & Holtzclaw, B. J. (2021) · Western Journal of Nursing Research · doi:10.1177/01939459211005710 · Cited by 14
Seasonal influenza vaccination of high-risk adults
Loubet, P., Loulergue, P., Galtier, F., & Launay, O. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1188696 · Cited by 14
Lassen, M. C. H., Johansen, N. D., Modin, D., Nealon, J., Samson, S., Dufournet, M., Loiacono, M. M., Larsen, C. S., Jensen, A. M. R., Landler, N. E., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15498 · Cited by 10
Joosten, S. A. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101964 · Cited by 10
Sadarangani, S. P., Young, B. E., Lian, W., Phua, H. P., Chen, M. I.-C., Barr, I., Yeo, T. W., Dalan, R., & Chow, A. L. (2022) · npj Vaccines · doi:10.1038/s41541-022-00548-z · Cited by 10
How does geographical diversity shape vaccine efficacy?
Abavisani, M., Ansari, B., Ebadpour, N., & Sahebkar, A. (2024) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2024.13.4.271 · Cited by 9
Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination
Mohebbi, A., Eterafi, M., Fouladi, N., Golizadeh, M., Panahizadeh, R., Habibzadeh, S., Karimi, K., & Safarzadeh, E. (2023) · Current Microbiology · doi:10.1007/s00284-023-03432-8 · Cited by 8
Tarasova, A. A., Владимировна, К. Е., Лукушкина, Е. Ф., Kuzmichev, Y. G., & Костинов, М. П. (2016) · Вопросы современной педиатрии · doi:10.15690/vsp.v15i5.1623 · Cited by 8
Chronic Diseases and Influenza Vaccines
Lian, R., Zhang, H., An, Y., & Chen, Z. (2025) · Vaccines · doi:10.3390/vaccines13090936 · Cited by 7
Zheng, J.-Q., Lin, C.-H., Chen, C., Lin, Y., Chiu, C.-C., Yang, T. Y., Hsu, M., Fang, Y.-A., Hao, W., Liu, J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153434 · Cited by 7
The impact of glucose tolerance state on seropositivity rate after hepatitis B vaccination
Villacreses, M. M. C., Karnchanasorn, R., Ou, H., Samoa, R. A., Chuang, L., & Chiu, K. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-07163-x · Cited by 6
Young, B. E., Sadarangani, S. P., Yew, H. S., Yung, C. F., Leo, Y., Chen, M. I.-C., & Wilder‐Smith, A. (2017) · Trials · doi:10.1186/s13063-017-1808-8 · Cited by 5
Vaccination of patients with diabetes mellitus
Shestakova, M. V., Nikonova, T. V., Барышева, В. О., & Mokrysheva, N. G. (2022) · Diabetes Mellitus · doi:10.14341/dm12833 · Cited by 4
Chen, Z., & Yang, T. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2458814 · Cited by 4
Eczacılıkta Güncel Araştırmalar
Yamalı, C., Erdönmez, E., Yuca, H., Kalaycı, B., Gökgöz, S., Paşayeva, L., Arslan, A. K. K., Şerbetçi, T., Aydoğan, Y. M., Yüce, H., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2541 · Cited by 3
COVID-19 in Type 1 Diabetes Mellitus adult patients; effect of infection and vaccination
Albatayneh, E. M., Alabdallat, Y. J., Ayash, H., Abduh, M. S., & Mahgoub, S. S. (2022) · Medical Science · doi:10.54905/disssi/v26i122/ms155e2244 · Cited by 1
Investigating the Role of Insulin Receptor Signaling in B Lymphocyte Function
Chan, Y. T. (2019) · TSpace (University of Toronto)
Efficacité de la vaccination antigrippale saisonnière chez les patients présentant un diabète
Casanova, L. (2022) · theses.fr (ABES) · doi:10.70675/00231d4czebf1z400bzbb7cz1e2edb1b5de1
Metadata
- Authors
- Seo, Y. B., Baek, J. H., Lee, J., Song, J. Y., Lee, J. S., Cheong, H. J., & Kim, W. J.
- Affiliations
- Hallym University (KR)
- Inha University (KR)
- Korea University (KR)
- Venue
- Clinical and Vaccine Immunology
- Publisher
- American Society for Microbiology
- Published
- 2015-11
- Volume
- 22
- Issue
- 11
- Pages
- 1160-1165
- ISSN
- 1556-679X (ISSN-L)
- 1556-6811
- PMC
- PMC4622108
- OpenAlex
- W2255324844
- Cited by
- 32
- References
- 18
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 4 · 2022: 8 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 2
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Clinical and Vaccine Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Korea University Guro Hospital
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- influenza vaccination, type 2 diabetes, immunogenicity, vaccine safety, hemagglutination inhibition antibodies, seroprotection, H1N1 influenza, local vaccine reactions, elderly patients
- MeSH terms
- Seroconversion, Adjuvants, Immunologic, Age Factors, Aged, Antibodies, Viral, Diabetes Mellitus, Type 2, Female, Hemagglutination Inhibition Tests, Humans, Influenza, Human, Influenza Vaccines, Male, Middle Aged, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.